主页 > 医学新闻 >
【drug-news】雅培获得Verax公司 Platelet PGD(R) 的全球
- Verax Platelet PGD(R) Test Designed to Detect Presence of Bacterial
Contamination in Platelets Prior to Transfusion -
ABBOTT PARK, Ill, Oct. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT)
today announced that it has entered into an exclusive distribution
agreement with Verax Biomedical Inc., a leading developer of rapid tests
for detecting bacterial contaminants found in blood cells and tissue. Under
the terms of the agreement, Abbott receives worldwide rights to market and
distribute the Verax Platelet PGD(R) Test, which is currently being
evaluated in clinical trials. The Platelet PGD Test is an easy-to-use,
disposable device designed to detect the presence of a broad range of
bacterial contaminants in platelets just prior to transfusion. No
additional terms of the agreement were disclosed.
Bacterial contamination in platelets and red blood cells represents the
single greatest source of risk for lethal infections in transfusion
medicine today. An estimated 10 million platelet units are transfused each
year to patients in North America, Europe and Asia, and experts estimate
that as many as 1 in every 2,000 units could be contaminated with bacteria.
To combat this risk, the American Association of Blood Banks requires
all its members to implement methods to limit and detect bacterial
contamination in platelets. Current culture testing methods can take up to
three days before results are available. In comparison, the Verax Platelet
PGD Test, which is designed to target antigens found on all species of
bacteria known to be pathogenic to humans, is intended to provide results
in less than 30 minutes. Clinical studies of the test are currently ongoing
and are expected to generate data for a 510 filing with the U.S. Food
and Drug Administration.
"Our partnership with Verax will allow us to provide our blood bank and
hospital customers with an important test to address the risk of bacterial
contamination in transfusion medicine, and further emphasizes Abbott's
commitment to enhance the safety of the world's blood supply," said Jeff
Binder, senior vice president, diagnostic operations, Abbott.
"This agreement represents a significant milestone in our company's
strategic growth," said Jim Lousararian, chief executive officer, Verax
Biomedical. "Abbott's vast experience and knowledge of the blood bank
industry make them a wonderful partner for us."
The Verax Platelet PGD Test is based on Verax Biomedical's proprietary
Pan Genera(R) Detection technology, which targets common antigens found on
the surface of all species of bacteria known to be pathogenic to humans.
Clinical trials of the test are currently underway at University Hospitals
Case Medical Center at the Cleveland Clinic in Cleveland, Ohio; and
Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire.
About Verax Biomedical
Based in Worcester, Mass., Verax Biomedical is a leader in the
development of rapid tests designed to detect a broad range of bacterial
contaminants based upon its proprietary Pan Genera(R) Detection (PGD)
technology. The first target application for its technology is to test for
the presence of bacterial contaminants in platelets. Bacterial contaminants
in platelets and red blood cells represent the greatest lethal infectious
risks in transfusion medicine today, and no rapid, simple methods are
presently available to effectively address this threat.
For additional information, visit Verax Biomedical, Inc. at
veraxbiomedical.com.
About Abbott Diagnostics
Abbott Diagnostics is a global leader in in vitro diagnostics and
offers a broad range of innovative instrument systems and tests for
hospitals, reference labs, blood banks, physician offices and clinics. With
more than 69,000 institutional customers in more than 100 countries,
Abbott's diagnostic products offer customers automation, convenience, cost
effectiveness and flexibility. The history of Abbott Diagnostics is filled
with examples of first-of-a-kind products and significant technological
advancements. For additional information, visit Abbott Diagnostics online
at abbottdiagnostics.com.
*Verax Platelet PGD is a registered trademark of Verax Biomedical, Inc. 我认领这篇了 感觉翻译得不很顺，请战友多提宝贵意见。谢谢。
雅培与Verax生物制药公司签署了快速检测血小板细菌方的全球独家销售权协议。
Verax Platelet PGD(R) 检测是旨在发现血小板输注前是否存在细菌污染。
雅培PARK，Ill，10，20/PRNewswire-FirstCall/雅培
雅培今天宣布了它们已与Verax生物制药公司签署独家销售协议 ，Verax公司首先开发出快速测试方法，检测血细胞、组织中的细菌污染。
.根据协议条款，雅培获得全球市场销售权，并推广Verax Platelet PGD(R) 检测，这一方法目前正在进行临床验证。此方法简便易行，一次性设备在血小板输注前被用于检测多种细菌污染的存在，协议中其他款项未透露。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-10 17:28
医学,生命科学网